CytomX snags cancer drug deal with Regeneron - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 61 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 68%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

$REGN, $CTMX land $2 billion bio-bucks deal with $30M upfront to power up cancer-fighting drugs

CytomX Therapeutics Inc., which four months ago cut 40% of its staff after a clinical trial failure, said Thursday it snagged a $30 million upfront payment with a cancer drug research and development collaboration that ultimately could total $2 billion.

That trading point still is far off CytomX's 52-week high of $7.46 per share, but the rise indicates Wall Street's belief that CytomX is heading in the right direction with its third partnership with a large drugmaker in the bispecific antibody space. The process with what CytomX calls its Probody creates so-called antibody-drug conjugates that widen a drug's"therapeutic window" by increasing safety — since the drug doesn't link to healthy cells — and boosts the drug's efficacy, said CytomX CEOIt doesn't always work out as planned. CytomX's conditionally activated antibody-drug conjugate praluzatamab ravtansine this summer failed a mid-stage clinical trial in triple-negative breast cancer.

Regeneron will pay $30 million upfront to CytomX with"bio-bucks" — research, development and sales milestones — that can trigger up to $2 billion more. Regeneron, initially coupling up its Veloci-Bi bispecific antibody platform, will have the opportunity to nominate additional targets.The scientific validation of another deal is important for CytomX; so, too, is the money at a time when drug developers are trimming programs, staffing and other costs.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 78. in BE

Belgique Dernières Nouvelles, Belgique Actualités